Key facts
- This page summarizes John R. Chiminski's Form 4 filing for Bruker Cellular Analysis, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Oct 2023, 15:41.
John R. Chiminski - 02 Oct 2023 Form 4 Insider Report for Bruker Cellular Analysis, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 02 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Oct 2023, 15:41:09 UTC
- Prior SEC filing
- 01 Jun 2023
- Next SEC filing
- 10 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine Nassi, Attorney-in-fact for John R. Chiminski
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John R. Chiminski filed Form 4 for Bruker Cellular Analysis, Inc. on 03 Oct 2023.
Change
- Previous filing in this sequence was filed on 01 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CELL
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -71,225
- Change %
- -63%
- Price
- Shares after
- 41,240
- Date
- 02 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2
CELL
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -41,240
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Oct 2023
- Ownership
- Direct
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration").
Footnote F2
Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration.
Footnote F3
Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration.
Footnote F4
Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration.